Executive Team

Michael Kope

President, Chief Executive Officer, and Co-founder

Mr. Kope received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; as Director of Corporate Development for Aviron, and for MedImmune, Inc.; and as CEO and officer of a number of start-ups in the biotechnology space. He specializes in business development and consulting, and is widely experienced with biotechnology organizations. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.

Aubrey de Grey, Ph.D.

Chief Science Officer and Co-founder

Dr. de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations. Click here to download a copy of Dr. de Grey's CV.

David Brindley

Director of Alliances

David is an international thought-leader in healthcare risk management, with a particular interest in regenerative medicines. His multi-disciplinary research seeks to evaluate and develop systematic, rigorous and transparent risk management tools supporting the translation of life-science innovations into commercially viable products and services.

In all cases, David strives to conduct research that is both academically rigorous and commercially practicable. His expertise spans the ‘Valley of Death,’ encompassing regulation, engineering and finance.

At the SENS Research Foundation David leads all aspects of the Alliance Programs. He currently manages the CTSCC (CASMI Translational Stem Cell Consortium) program, the Alliance program and the development of a Rejuvenation Biotechnology Translational Consortium (RBTC). Within CTSCC, David leads all research activities pertaining to risk. David’s work can be found in a range of high impact journals including Nature, Nature Biotechnology, Nature Medicine and Cell Stem Cell. Additionally, David serves as an Editorial Board member for a range of international academic and industrial journals. David also produces a popular blog, Cell Therapy Industry 2027, with the Centre for the Commercialisation of Regenerative Medicine.

David is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. David has successfully passed the Charted Analyst in Alternative Investments (CAIA) Level 1 examination. David indulges his entrepreneurial spirit through his consultancy, Translation Ventures Ltd, providing timely and pragmatic advice and training to a range of stakeholders in healthcare translation, including the venture capital community. Additionally, David is a strategic advisor to a number of SMEs pursuing excellence in healthcare risk management solutions, including Spoonful of Sugar and Oxford Risk.

David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honors and his Masters, investigating the commercialisation of regenerative therapies, jointly at the Harvard Stem Cell Institute and Harvard Business School (Prof. William Sahlman). David received a DPhil (PhD) in Musculoskeletal Sciences at the University of Oxford.